|1.||Marr, Joachim: 9 articles (05/2012 - 09/2004)|
|2.||Heithecker, R: 6 articles (09/2003 - 03/2000)|
|3.||Helmerhorst, Frans M: 5 articles (01/2014 - 01/2009)|
|4.||Gerlinger, Christoph: 5 articles (05/2012 - 04/2002)|
|5.||Kunz, Michael: 5 articles (05/2012 - 06/2007)|
|6.||Sampson-Landers, Carole: 5 articles (09/2009 - 09/2004)|
|7.||Hanes, Vladimir: 5 articles (01/2008 - 09/2005)|
|8.||Ibáñez, Lourdes: 5 articles (02/2006 - 04/2004)|
|9.||Trummer, Dietmar: 4 articles (01/2015 - 04/2012)|
|10.||Lidegaard, Øjvind: 4 articles (10/2014 - 01/2009)|
09/01/2008 - "This drospirenone-containing COC has been shown to be effective in reducing both inflammatory and noninflammatory acne lesions."
09/01/2007 - "With the accumulating evidence on the efficacy and safety of drospirenone-containing hormonal preparations, this formulation provides dermatologists with a new treatment option for acne and other hyperandrogenic disorders."
04/01/2008 - "Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial."
01/01/2008 - "Several studies have shown that drospirenone, a progestin available in certain OCs, minimizes the potential negative effect the progestin has on acne. "
01/01/2007 - "Clinical trials indicate that drospirenone/ethinylestradiol 3mg/20microg (24/4) is a good long-term contraceptive option, and additionally offers relief of symptoms that characterise PMDD and has a favourable effect on moderate acne vulgaris."
02/01/2006 - "Non-obese, young patients (n = 31) with hyperinsulinaemic hyperandrogenism were started on Flu-Met (21/28 days) and randomized to receive in addition either a drospirenone oral contraceptive or a transdermal contraceptive for 6 months. "
05/01/2015 - "Drospirenone containing combined oral contraceptive (COC) is found to have more favorable effects on lipid profiles, hsCRP levels, insulin resistance and hyperandrogenism when compared with the CMA containing COC and appears to be more beneficial for the long-term cardiovascular and metabolic aspects of PCOS."
12/01/2010 - "evaluate the efficacy of an estroprogestin EP containing 20 mcg ethinilestradiol (EE) and 3 mg drospirenone (DRSP) in the treatment of hyperandrogenism. "
12/01/2010 - "[Short-term effect of an estroprogestin containing ethinylestradiol 20 mcg + drospirenone 3 mg in 24+4 regimen at hormonal and cutaneous level in ovarian hyperandrogenism]."
01/01/2006 - "To prove the clinical efficiency over hyperandrogenism in women with PCOS after the application of the combined oral contraceptive Yasmin containing 30 mcg ethynilestradiol and 2 mg drospirenone. "
04/01/2008 - "Treatment of hirsutism with combined pill containing drospirenone."
02/01/2006 - "Drospirenone/ethinyl estradiol combination exerts significant antiandrogenic activity and is effective in improving facial hirsutism. "
02/01/2006 - "Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism."
11/01/2011 - "A prospective randomized trial was conducted to compare the clinical efficacy of two oral contraceptives containing drospirenone in the treatment of hirsutism in women. "
11/01/2011 - "A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism."
12/01/2007 - "A continuous combined HRT containing 17beta-estradiol (E(2)) 1 mg plus drospirenone (DRSP) 2 mg is effective in relieving menopausal symptoms and preventing postmenopausal osteoporosis. "
10/01/2005 - "The combination of 17beta-estradiol with drospirenone offers a safe and effective medication for decreasing bone turnover and preventing postmenopausal bone loss in postmenopausal women."
03/01/2004 - "Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis."
03/01/2004 - "To evaluate the combination of 17beta-estradiol and continuous drospirenone for the prevention of postmenopausal osteoporosis. "
|5.||Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
03/01/2007 - "Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome."
06/01/2004 - "The aim of this study was to investigate the effects of the new estro-progestinic containing the antimineralcorticoid progestogen drospirenone (DRSP) in women with polycystic ovary syndrome (PCOS). "
01/01/2011 - "Effects of drospirenone pill in Indian women with polycystic ovary syndrome."
02/01/2010 - "We sought to verify if an oral contraceptive (OC) containing drospirenone affects the cardiovascular risk of patients with polycystic ovary syndrome (PCOS). "
02/01/2010 - "Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study."
|1.||Ethinyl Estradiol (Estinyl)
|7.||Combined Oral Contraceptives
|8.||Contraceptive Agents (Contraceptives)
|1.||Contraception (Birth Control)
|2.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|5.||Female Contraceptive Devices (Vaginal Ring)